Cortechs.ai | Restriction Spectrum Imaging (RSI) improves cancer detection

Restriction Spectrum Imaging (RSI) improves cancer detection

Compares the diagnostic performance of restriction spectrum imaging (RSI), with that of conventional multi-parametric (MP) magnetic resonance imaging (MRI) for prostate cancer (PCa) detection in a blinded reader-based format. 2016.

[button]Download[/button]

More Resources

12/18/2025

Reimbursement Essentials for Quantitative Imaging: Key Takeaways From Our Expert Webinar

Our reimbursement webinar walked through best practices for billing, coding, and securing payment for NeuroQuant and OnQ Prostate, helping inform providers.

12/09/2025

SNO 2025 Recap: Collaboration Driving Innovation in Neuro-Oncology

The 2025 Society for Neuro-Oncology meeting was more than a conference, it was a hub of collaboration and conversation among industry leaders and physicians.

11/19/2025

Philips and Cortechs.ai extend partnership to advance quantitative neuroimaging and strengthen Philips’ leadership in precision diagnostics in neurology

The companies will integrate Cortechs.ai’s advanced AI-enabled neuroimaging analytics directly into Philips’ MR systems.

11/17/2025

Unlocking the Value of NeuroQuant Reports: Different Use Cases Across Clinical Practice

From neurodegeneration and demyelination to development, trauma, and seizures, NeuroQuant supports better decision‑making, communication, and patient care

11/17/2025

Case Study: Augmenting Prostate Imaging Programs with OnQ™ Prostate

Discover how Imaging Healthcare Specialists integrated OnQ™ Prostate to enhance lesion visibility, boost diagnostic confidence, and improve communication.

11/04/2025

NeuroQuant Dementia in Different Use Cases 

NeuroQuant transforms brain imaging into a measurable biomarker for neurodegeneration by combining volumetric data with clinical expertise.
Scroll to Top